ID   VAV_RAT                 Reviewed;         843 AA.
AC   P54100;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 1.
DT   02-OCT-2024, entry version 166.
DE   RecName: Full=Proto-oncogene vav;
DE   AltName: Full=p95;
GN   Name=Vav1; Synonyms=Vav;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=10395673;
RA   Song J.S., Haleem-Smith H., Arudchandran R., Gomez J., Scott P.M.,
RA   Mill J.F., Tan T.-H., Rivera J.;
RT   "Tyrosine phosphorylation of Vav stimulates IL-6 production in mast cells
RT   by a Rac/c-Jun N-terminal kinase-dependent pathway.";
RL   J. Immunol. 163:802-810(1999).
CC   -!- FUNCTION: Couples tyrosine kinase signals with the activation of the
CC       Rho/Rac GTPases, thus leading to cell differentiation and/or
CC       proliferation.
CC   -!- SUBUNIT: Interacts with SHB (By similarity). Interacts with APS, DOCK2,
CC       GRB2, GRB3, DOCK2, SLA, TEC and ZNF655/VIK. Interacts with SIAH2;
CC       without leading to its degradation. Associates with BLNK, PLCG1, GRB2
CC       and NCK1 in a B-cell antigen receptor-dependent fashion. Interacts with
CC       CBLB; which inhibits tyrosine phosphorylation and down-regulates
CC       activity. May interact with CCPG1. Interacts with CLNK. Interacts with
CC       THEMIS2 (By similarity). Interacts with NEK3 and this interaction is
CC       prolactin-dependent. Interacts with ITK. Interacts with PTK2B/PYK2 (By
CC       similarity). Interacts with HCK. Interacts with PTK2B/PYK2. Interacts
CC       (via SH2 domain) with SYK (By similarity). Interacts with ANKRD54.
CC       Interacts with CD6 (By similarity). Interacts with LCP2; this
CC       interaction plays a role in TCR-mediated cytokine production (By
CC       similarity). {ECO:0000250|UniProtKB:P15498,
CC       ECO:0000250|UniProtKB:P27870}.
CC   -!- DOMAIN: The DH domain is involved in interaction with CCPG1.
CC       {ECO:0000250}.
CC   -!- PTM: Phosphorylated by FYN. Phosphorylated on tyrosine residues by HCK
CC       in response to IFNG and bacterial lipopolysaccharide (LPS) (By
CC       similarity). {ECO:0000250}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U39476; AAA98606.1; -; mRNA.
DR   AlphaFoldDB; P54100; -.
DR   SMR; P54100; -.
DR   IntAct; P54100; 3.
DR   STRING; 10116.ENSRNOP00000064264; -.
DR   PhosphoSitePlus; P54100; -.
DR   PaxDb; 10116-ENSRNOP00000064264; -.
DR   AGR; RGD:3951; -.
DR   RGD; 3951; Vav1.
DR   eggNOG; KOG2996; Eukaryota.
DR   InParanoid; P54100; -.
DR   PhylomeDB; P54100; -.
DR   Reactome; R-RNO-114604; GPVI-mediated activation cascade.
DR   Reactome; R-RNO-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-RNO-1433557; Signaling by SCF-KIT.
DR   Reactome; R-RNO-193648; NRAGE signals death through JNK.
DR   Reactome; R-RNO-2029482; Regulation of actin dynamics for phagocytic cup formation.
DR   Reactome; R-RNO-2871796; FCERI mediated MAPK activation.
DR   Reactome; R-RNO-2871809; FCERI mediated Ca+2 mobilization.
DR   Reactome; R-RNO-389359; CD28 dependent Vav1 pathway.
DR   Reactome; R-RNO-416482; G alpha (12/13) signalling events.
DR   Reactome; R-RNO-4420097; VEGFA-VEGFR2 Pathway.
DR   Reactome; R-RNO-512988; Interleukin-3, Interleukin-5 and GM-CSF signaling.
DR   Reactome; R-RNO-5218920; VEGFR2 mediated vascular permeability.
DR   Reactome; R-RNO-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling.
DR   Reactome; R-RNO-8980692; RHOA GTPase cycle.
DR   Reactome; R-RNO-9013149; RAC1 GTPase cycle.
DR   Reactome; R-RNO-9013404; RAC2 GTPase cycle.
DR   Reactome; R-RNO-9013408; RHOG GTPase cycle.
DR   Reactome; R-RNO-9027284; Erythropoietin activates RAS.
DR   Reactome; R-RNO-912631; Regulation of signaling by CBL.
DR   Reactome; R-RNO-9748787; Azathioprine ADME.
DR   Reactome; R-RNO-983695; Antigen activates B Cell Receptor (BCR) leading to generation of second messengers.
DR   PRO; PR:P54100; -.
DR   Proteomes; UP000002494; Unplaced.
DR   GO; GO:0005911; C:cell-cell junction; ISO:RGD.
DR   GO; GO:0005737; C:cytoplasm; ISO:RGD.
DR   GO; GO:0005085; F:guanyl-nucleotide exchange factor activity; ISO:RGD.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0140031; F:phosphorylation-dependent protein binding; ISO:RGD.
DR   GO; GO:0001784; F:phosphotyrosine residue binding; ISO:RGD.
DR   GO; GO:0048468; P:cell development; TAS:RGD.
DR   GO; GO:0016477; P:cell migration; IBA:GO_Central.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; ISO:RGD.
DR   GO; GO:0006955; P:immune response; ISO:RGD.
DR   GO; GO:0002768; P:immune response-regulating cell surface receptor signaling pathway; IEP:RGD.
DR   GO; GO:0007229; P:integrin-mediated signaling pathway; ISO:RGD.
DR   GO; GO:0035556; P:intracellular signal transduction; ISO:RGD.
DR   GO; GO:0042267; P:natural killer cell mediated cytotoxicity; ISO:RGD.
DR   GO; GO:0030593; P:neutrophil chemotaxis; ISO:RGD.
DR   GO; GO:0006909; P:phagocytosis; ISO:RGD.
DR   GO; GO:0045785; P:positive regulation of cell adhesion; ISO:RGD.
DR   GO; GO:0045954; P:positive regulation of natural killer cell mediated cytotoxicity; ISO:RGD.
DR   GO; GO:0072593; P:reactive oxygen species metabolic process; ISO:RGD.
DR   GO; GO:0008361; P:regulation of cell size; ISO:RGD.
DR   GO; GO:0042110; P:T cell activation; ISO:RGD.
DR   GO; GO:0030217; P:T cell differentiation; ISO:RGD.
DR   CDD; cd20867; C1_VAV1; 1.
DR   CDD; cd21262; CH_VAV1; 1.
DR   CDD; cd01223; PH_Vav; 1.
DR   CDD; cd00160; RhoGEF; 1.
DR   CDD; cd10405; SH2_Vav1; 1.
DR   CDD; cd11979; SH3_VAV1_1; 1.
DR   CDD; cd11976; SH3_VAV1_2; 1.
DR   Gene3D; 3.30.60.20; -; 1.
DR   Gene3D; 1.10.418.10; Calponin-like domain; 1.
DR   Gene3D; 1.20.900.10; Dbl homology (DH) domain; 1.
DR   Gene3D; 2.30.29.30; Pleckstrin-homology domain (PH domain)/Phosphotyrosine-binding domain (PTB); 1.
DR   Gene3D; 3.30.505.10; SH2 domain; 1.
DR   Gene3D; 2.30.30.40; SH3 Domains; 2.
DR   InterPro; IPR022613; CAMSAP-like_CH_dom.
DR   InterPro; IPR001715; CH_dom.
DR   InterPro; IPR036872; CH_dom_sf.
DR   InterPro; IPR035899; DBL_dom_sf.
DR   InterPro; IPR000219; DH-domain.
DR   InterPro; IPR001331; GDS_CDC24_CS.
DR   InterPro; IPR002219; PE/DAG-bd.
DR   InterPro; IPR011993; PH-like_dom_sf.
DR   InterPro; IPR001849; PH_domain.
DR   InterPro; IPR037832; PH_Vav.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR036860; SH2_dom_sf.
DR   InterPro; IPR036028; SH3-like_dom_sf.
DR   InterPro; IPR001452; SH3_domain.
DR   InterPro; IPR003096; SM22_calponin.
DR   InterPro; IPR035879; VAV1_SH2.
DR   InterPro; IPR035730; VAV1_SH3_1.
DR   InterPro; IPR035729; VAV1_SH3_2.
DR   PANTHER; PTHR45818; PROTEIN VAV; 1.
DR   PANTHER; PTHR45818:SF2; PROTO-ONCOGENE VAV; 1.
DR   Pfam; PF00130; C1_1; 1.
DR   Pfam; PF11971; CAMSAP_CH; 1.
DR   Pfam; PF00169; PH; 1.
DR   Pfam; PF00621; RhoGEF; 1.
DR   Pfam; PF00017; SH2; 1.
DR   Pfam; PF00018; SH3_1; 1.
DR   Pfam; PF07653; SH3_2; 1.
DR   PRINTS; PR00401; SH2DOMAIN.
DR   PRINTS; PR00452; SH3DOMAIN.
DR   PRINTS; PR00888; SM22CALPONIN.
DR   SMART; SM00109; C1; 1.
DR   SMART; SM00033; CH; 1.
DR   SMART; SM00233; PH; 1.
DR   SMART; SM00325; RhoGEF; 1.
DR   SMART; SM00252; SH2; 1.
DR   SMART; SM00326; SH3; 2.
DR   SUPFAM; SSF47576; Calponin-homology domain, CH-domain; 1.
DR   SUPFAM; SSF48065; DBL homology domain (DH-domain); 1.
DR   SUPFAM; SSF50729; PH domain-like; 1.
DR   SUPFAM; SSF55550; SH2 domain; 1.
DR   SUPFAM; SSF50044; SH3-domain; 1.
DR   PROSITE; PS50021; CH; 1.
DR   PROSITE; PS00741; DH_1; 1.
DR   PROSITE; PS50010; DH_2; 1.
DR   PROSITE; PS50003; PH_DOMAIN; 1.
DR   PROSITE; PS50001; SH2; 1.
DR   PROSITE; PS50002; SH3; 2.
DR   PROSITE; PS00479; ZF_DAG_PE_1; 1.
DR   PROSITE; PS50081; ZF_DAG_PE_2; 1.
PE   2: Evidence at transcript level;
KW   Guanine-nucleotide releasing factor; Metal-binding; Phosphoprotein;
KW   Proto-oncogene; Reference proteome; Repeat; SH2 domain; SH3 domain; Zinc;
KW   Zinc-finger.
FT   CHAIN           1..843
FT                   /note="Proto-oncogene vav"
FT                   /id="PRO_0000080982"
FT   DOMAIN          1..119
FT                   /note="Calponin-homology (CH)"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00044"
FT   DOMAIN          194..373
FT                   /note="DH"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00062"
FT   DOMAIN          402..504
FT                   /note="PH"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00145"
FT   DOMAIN          590..658
FT                   /note="SH3 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00192"
FT   DOMAIN          669..763
FT                   /note="SH2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00191"
FT   DOMAIN          780..840
FT                   /note="SH3 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00192"
FT   ZN_FING         515..564
FT                   /note="Phorbol-ester/DAG-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00226"
FT   MOD_RES         824
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:P15498"
FT   MOD_RES         842
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:P27870"
SQ   SEQUENCE   843 AA;  97954 MW;  C4A5CACD45FCB80E CRC64;
     MELWRQCTHW LIQCRVLPPS HRVTWEGAQV CELAQALRDG VLLCQLLNNL LPHAINLREV
     NLRPQMSQFL CLKNIRTFLS TCCEKFGLKR SELFEAFDLF DVQDFGKVIY TLSALSWTPI
     AQNKGIMPFP TEDSALGDED IYSGLSDQID DTAEEDEDLY DCVENEEAEG DEIYEDLMRS
     ESVPTPPKMT EYDKRCCCLR EIQQTEEKYT DTLGSIQQHF MKPLQRFLKP QDMETIFVNI
     EELLSVHTHF LKELKDALSG PGATMLYQVF IKYKERFLVY GRYCSQVESA IKHLDQVATA
     REDVQMKLEE CSQRANNGRF TLRDLLMVPM QRVLKYHLLL QELVKHTQDT TEKENLRLAL
     DAMRDLAQCV NEVKRDNETL RQITNFQLSI ENLDQSLANY GRPKIDGELK ITSVERRSKT
     DRYAFLLDKA LLICKRRGDS YDLKASVNLH SFQVRDDSSG ERDNKKWSHM FLLIEDQGAQ
     GYELFFKTRE LKKKWMEQFE MAISNIYPEN ATANGHDFQM FSFEETTSCK ACQMLLRGTF
     YQGYRCYRCR APAHKECLGR VPPCGRQDFS GTMKKDKLHR RAQDKKRNEL GLPKMEVCQE
     YYGIPPPPGA FGPFLRLNPG DIVELTKAEA EHTWWEGRNT ATNEVGWFPC NRVRPYVHGP
     PQDLSVHLWY AGPMERAGAE GILTNRSDGT YLVRQRVKDT AEFAISIKYN VEVKHIKIMT
     SEGLYRITEK KAFRGLPELV EFYQQNSLKD CFKSLDTTLQ FPYKEPERRA INKPPVGSTK
     YFGTAKARYD FCARDRSELS LKEGDIIKIL NKKGQQGWWR GEIYGRIGWF PSNYVEEDYS
     EYC
//
